Blog

25/11/2021

Expanding on our 2021 Spring Newsletter, we have gathered new information regarding the impact and recommendations of the COVID-19 vaccines for people with MS.

25/11/2021

Winter is fast approaching, with days getting shorter, and temperatures dropping, which made us think – as the seasons change, does this impact upon a person’s MS? And if so, how?

25/11/2021

MS is most commonly diagnosed in young women, at a time when many will still be considering starting or expanding their family. As more disease modifying treatments (DMTs) become available, what are the latest recommendations regarding their use during pregnancy?

23/11/2021

MS Nurse PRO has been re-launched in Romania during an educational event attended by around 100 nurses and carers.

09/11/2021

The 2021 EMSPx MS Nurse PRO Conference expanded on the current evolution of MS medical treatment its impact on MS nursing.

09/11/2021

The 2021 EMSPx MS Nurse PRO Conference expanded on the impact of the Covid-19 pandemic on MS care, collecting best practices from different counties across Europe.

09/11/2021

The 2021 EMSPx MS Nurse PRO Conference emphasized the challenges encountered by the nursing community during the Covid-19 pandemic.

09/11/2021

Co-organised by MS Nurse PRO, the 2021 EMSP Conference put the MS nurse community at the center of the event! One of the focal points of the conference was the importance of a good patient-nurse relationship.

18/10/2021

Partake in MS NursED, an educational conference with panel of MS expert neurologists, nurses and patients to discuss ongoing challenges in MS management!

15/01/2021

EMSP have partnered up with MoveToSport – and Almirall, to make the “Keep Moving with Multiple Sclerosis” online MS exercise program (created by the MoveToSport team) available in several European languages.

01/01/2021

MS Nurse PROfessional got a facelift! We gave the site a fresh, new look, adding novel features to improve the functionality and enhance your learning experience.

29/05/2020

The European Commission (EC) has approved ozanimod for the treatment of adults with relapsing-remitting MS (RRMS) who have active disease based on clinical or imaging features.